Cardiac Science Powerheart Approval Revitalizes Stock In November
This article was originally published in The Gray Sheet
Executive Summary
The possibility of the next-generation Powerheart bedside monitor-defibrillator emerging as a standard fixture in the acute-care setting helped to almost double Cardiac Science's stock price for November